Clostridioides (Clostridium) difficile Pacemaker Infection

Anna Berkefeld,[1] Fabian K. Berger,[2] Barbara C. Gärtner,[2] Nina Wantia,[3] Anatol Prinzing,[4] Karl-Ludwig Laugwitz,[1] Dirk H. Busch,[3,5] and Kathrin Rothe[3]

[1]Department of Internal Medicine I, Technical University of Munich, School of Medicine, Munich, Germany, [2]Institute of Medical Microbiology and Hygiene, German National Reference Center for Clostridioides (Clostridium) difficile, University of Saarland, Homburg/Saar, Germany, [3]Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, School of Medicine, Munich, Germany, [4]Department of Cardiovascular Surgery, German Heart Centre Munich, Technical University of Munich, School of Medicine, Munich, Germany, and [5]German Centre for Infection Research (DZIF), partner site Munich, Munich, Germany

Clostridioides difficile is the leading cause of antibiotic-associated nosocomial diarrhea, but extra-intestinal manifestations are rare. We describe the first documented case of bacteraemia with pacemaker pocket and lead infection with the toxigenic *C. difficile* ribotype 014 with a lack of abdominal symptoms. The patient underwent pacemaker extraction and treatment with intravenous and oral vancomycin. Genotyping and molecular subtyping revealed clonality between pacemaker and intestinal isolates. This case illustrates the risk of intravascular device infections due to *C. difficile*. Even asymptomatic *C. difficile* colonization might pose a risk for prosthetic material infection.

Keywords. cardiac implantable electronic device; *Clostridioides (Clostridium) difficile*; lead endocarditis; pacemaker infection.

Clostridioides (Clostridium) difficile is an anaerobic, spore-forming gram-positive bacterium that causes nosocomial diarrhea with high mortality and morbidity. Previous antibiotic treatment is the main risk factor for *C. difficile* infection (CDI), and the clinical appearance of CDI varies from asymptomatic carriers to severe pseudomembranous colitis and toxic megacolon [1]. Approximately 11%–27% of all CDI cases seem to be community acquired [2]. Up to 30% of adult hospitalized patients and 0%–15% of healthy adults are estimated to be asymptomatically colonized [3]. The major pathogenic factors expressed by *C. difficile* are enterotoxin A and cytotoxin B, but more virulent strains can express a third "binary toxin" encoded by *cdtAB* [4]. The strains associated with outbreaks and severe infections are ribotypes 078 and 027 [5]. In Europe RT027, RT001, RT014, and RT020 are dominant, with regional differences [6]. Extra-intestinal *C. difficile* manifestations are rare given the high incidence of intestinal CDI. The majority of extra-intestinal manifestations are either abdominopelvic infections, wound infections after antibiotic exposure, or wound infections after gastrointestinal surgery [7]. *C. difficile* bacteremia is mainly polymicrobial and primarily seen in patients with abdominal pathologies. Mortality can be as high as 35%; however, patients usually have severe underlying medical conditions [8].

Graphical Abstract

Clostridioides (Clostridium) difficile pacemaker infection

C. difficile pacemaker-infection with device-associated endocarditis in patient with asymptomatic C. *difficile* colonization

Successful treatment with device removal and prolonged course of intravenous and oral vancomycin followed by tapering regimen and reimplantation

With rising numbers of implanted cardiac electronic devices and high incidence of C. difficile infections/colorizations clinical awareness and treatment recommendations for extraintestinal C. *difficile* infections are needed

Berkefeld et al. 2020

Infections of cardiovascular implantable electronic devices are increasing due to a rising number of implanted devices and more complex implantation procedures, with an incidence of 0.5%–3.4%. Bacterial colonization can occur during implantation or hematogenously [9], and the most common pathogens are staphylococcal species, followed by gram-negative pathogens, streptococci, enterococci, and anaerobic species [10]. Pocket infection with bacteremia and lead-associated endocarditis is associated with higher morbidity and mortality compared with pocket infection alone. The presence of ghosts after lead extraction is associated with infective endocarditis and leads to increased mortality [11]. Standard treatment is complete device removal with antibiotic therapy and reimplantation at an alternate site after adequate antibiotic treatment [12].

To date, no *C. difficile* pacemaker pocket and lead infection has been described. We present a case of *C. difficile* pacemaker pocket and lead infection with bacteremia in a patient without gastrointestinal CDI symptoms. Written informed consent was obtained from the patient for publication.

CASE REPORT

A 75-year-old male was referred to our stroke unit from a secondary care hospital with acute ischemic stroke due to thrombotic occlusion of the M1 segment of the left A. cerebri media following coronary angiography and intervention for non-ST-elevation myocardial infarction. He was referred to our hospital with right-sided hemiplegia for successful mechanical thrombectomy. An aspiration pneumonia was treated empirically with piperacillin/tazobactam for a total of 7 days. Additionally, an electrocardiogram revealed recurrent sinus bradycardia with intermittent ventricular escape rhythm and third-degree sinoatrial block. He underwent 2-chamber pacemaker implantation (Medtronic Ensura, Dublin, Ireland). According to national recommendations, povidone-iodine solution was used for preoperative skin antisepsis (exposure

time 1 minute). No specific antibiotic prophylaxis was used for the procedure, as the patient was still under piperacillin/tazobactam at the time of pacemaker implantation. Postimplantation measurements and wound inspections were normal. The patient was discharged to a neurological rehabilitation facility 4 days after pacemaker implantation, a total of 16 days after initial admission.

He was readmitted after 7 days with fever and a hyperthermic, reddened pacemaker incision site. Laboratory examination revealed leucocytosis and elevated C-reactive protein. Blood cultures were collected before empirical antibiotic therapy with ampicillin/sulbactam was initiated. With suspected pacemaker pocket infection, system extraction was performed. Intraprocedural inspection of the pacemaker pocket revealed no pus but an old hematoma. Swab samples of pacemaker and pocket, as well as the explanted leads, were retained for microbiological diagnostic. The patient was transferred to our intensive care unit with persisting sinoatrial block for further monitoring and transesophageal echocardiography (TEE). TEE revealed mobile vegetation from the right atrium to the superior vena cava (Figure 1) consistent with the presence of ghosts, indicating bacterial colonization of the intravascular segment of the lead with device-associated endocarditis.

Five sets of blood cultures (BACTEC, Becton Dickinson, Franklin Lakes, NJ, USA) were positive on culture day 2 for *C. difficile* isolated on schaedler agar (Becton Dickinson, Franklin Lakes, NJ, USA). The pacemaker samples (swabs and lead culture) and pocket swab cultures were positive for *C. difficile* on culture day 2. In order to detect an intestinal colonization with *C. difficile,* a stool sample was obtained. Two toxigenic *C. difficile* strains and 1 nontoxigenic isolate were obtained from the stool cultures. All acquired isolates underwent antimicrobial testing and ribotyping. The minimum inhibitory concentration of the isolate from the pacemaker was 0.5 mg/L for vancomycin and 1 mg/L for metronidazole (Table 1). Genotyping detected the toxigenic ribotype RT014


Figure 1. Transesophageal echocardiography (TEE) results. A, TEE revealing mobile vegetation from the right atrium to the superior vena cava. B, Control TEE with elimination of endocarditis vegetation.

Table 1. Results of Antimicrobial Susceptibility Testing of the RT014 Isolate From Blood Cultures (According to EUCAST, Version 9.0, 2019) for *C. difficile*

Antimicrobial	Minimum Inhibitory Concentration, mg/L	Interpretation
Vancomycin	0.38	S
Metronidazole	0.75	S
Moxifloxacin	3.0	S
Benzylpenicillin	1.5	a
Ampicillin	3.0	a
Ampicillin/sulbactam	3.0	a
Piperacillin/tazobactam	6.0	a
Cefuroxime	>256	a
Cefepime	>256	a
Cefotaxime	>32	a
Ceftriaxone	>32	a
Imipenem	3.0	a
Meropenem	2.0	a
Ertapenem	2.0	a
Ciprofloxacin	16.0	a
Levofloxacin	8.0	a
Trimethoprim/sulfamehoxazole	>32	a
Teicoplanin	0.38	a
Clindamycin	4.0	a
Rifampicin	0.002	a
Clarithromycin	2.0	a

Abbreviations: EUCAST, European Committee on Antimicrobial Susceptibility Testing; S, susceptible.

aNo breakpoints for interpretation of results of susceptibility testing available.

(Clade 1, MLST sequence type 2) in the stool and pacemaker isolate. Clonality of the RT014 isolates was confirmed by whole-genome sequencing (cgMLST) [13]. Additionally, 1 RT020 (toxigenic) and 1 unclassified nontoxigenic isolate were detected in the stool sample, indicating mixed strain colonization. Detailed medical history of the patient uncovered no signs of previous *C. difficile* infection. The patient neither suffered from nor previously had contact with infectious diarrhea, and abdominal ultrasound revealed no pathologies. In our institution, prevalence of *C. difficile*–associated diarrhea is low (0.28 CDI cases/100 patients were reported in 2019).

Antibiotic treatment was switched to intravenous vancomycin and oral metronidazole according to susceptibility testing and under continuous drug monitoring. Laboratory tests revealed normalization of leukocytes and C-reactive protein. On the third day of treatment, oral antibiotic therapy was switched from metronidazole to vancomycin due to increasing liver enzymes. Repeated blood cultures and stool samples during therapy remained negative.

The patient was transferred back to the rehabilitation facility on day 23 of antibiotic treatment. Intravenous vancomycin was continued for a total of 30 days. To decolonize the intestine as a possible reservoir for reinfection, oral vancomycin was administered for a total of 42 days using a tapering regime

[14]. Seven days after discontinuation of oral vancomycin, the patient was readmitted for pacemaker reimplantation. Before reimplantation, TEE revealed complete elimination of vegetations (Figure 2). Repeated blood cultures and skin swabs of the groin, axilla, rump, and pacemaker pocket were negative for *C. difficile.* Colonoscopy showed no signs of intestinal inflammation but a few noninflamed sigmoid diverticula. However, toxigenic *C. difficile* was again isolated from follow-up stool samples, but genotyping revealed a different toxigenic RT005, indicating reinfection.

After 3 days of treatment with intravenous vancomycin, reimplantation of the pacemaker was performed on the contralateral side. The patient was released to a rehabilitation facility on day 5 with an oral vancomycin tapering regime for another 50 days. Upon a scheduled follow-up visit 2 months after reimplantation, normal pacemaker function with no sign of infection was documented.

DISCUSSION

To the best of our knowledge, no case of *C. difficile* pacemaker pocket and lead infection has been described previously. In the literature, 3 cases of *C. difficile* infection of endovascular grafts [15–17] and 1 case with infected epicardial patch could be identified [18].

Two cases of *C. difficile* infection of endovascular aortic graft had preceding abdominal pathologies and underwent surgical treatment in addition to intravenous vancomycin and metronidazole [15, 16].

One case with mycotic aneurysm of an axillo-bifemoral bypass after pseudomembranous colitis was treated with surgical debridement and intravenous ampicillin/sulbactam and metronidazole [17]. *C. difficile* infection of an epicardial patch occurred after transverse colectomy 9 years after patch implantation and was treated with patch removal and intravenous vancomycin and metronidazole [18]. Another case with mycotic abdominal aortic aneurysm caused by *C. difficile* is of special interest as the patient was an asymptomatic community-acquired carrier of *C. difficile* without any history of hospital admission 3 years before infection. He did, however, suffer from severe diverticulosis, and hematogenous spread from the colonized gut was postulated as the most likely origin of infection [19]. In all cases, the pathway of graft infection was most likely through bacteremia, as all patients had gastrointestinal pathologies and preceding antibiotic therapies. In these cases, surgical removal and prolonged antibiotic treatment was successful.

In contrast, in our case no underlying gastrointestinal pathologies or diarrhea was evident. One may speculate that even diverticulosis without active diverticulitis might act as a translocation route, leading to transient bacteremia and prosthetic material infection, especially as skin swabs remained negative. This finding is in contrast to other cases, where severe intestinal

pathologies were present with extra-intestinal *C. difficile* manifestations [7]. Possible pathomechanisms for *C. difficile* bacteremia are bacterial transfer in mucosal injury or bacterial translocation in disrupted mucosal barrier function [8, 20].

In our case, 3 *C. difficile* strains were detected in stool samples (2 toxigenic, 1 nontoxigenic), but only the toxigenic RT014 strain was isolated from pacemaker probes and blood cultures. Clonality of the RT014 strain might suggest hematogenous translocation to the bloodstream from the intestine. Coinfections by multiple different *C. difficile* ribotypes can occur, but data are lacking on the question of whether toxigenic strains or some ribotypes translocate more easily [8, 21].

The asymptomatic *C. difficile* reinfection after initial eradication in our patient might indicate a higher susceptibility for *C. difficile* colonization, but studies do not indicate a higher prevalence or reinfection risk of *C. difficile* when diverticulosis is present [22]. Notably, the majority of short-term *C. difficile* recurrences are relapses rather than reinfections [23, 24].

Infections of cardiac implantable electronic devices can occur hematogenously or more commonly due to contamination with skin flora at initial implantation [25]. This is particularly the case for early-onset infections within 6 months [26]. Hematogenous infection of cardiac implantable electronic devices usually presents late and without concomitant pocket infection. Seeding to an implanted device in patients with bacteremia is primarily described in infections due to *Staphylococcus aureus* [25] but rarely occurs with gram-negative pathogens [25, 27]. Therefore, another explanation for the presented *C. difficile* pacemaker infection is surgical site infection due to skin colonization by *C. difficile*.

In patients with CDI, skin colonization of multiple body sites including the chest, groin, forearms, and hands has been shown [28]. Asymptomatic toxigenic *C. difficile* colonization is found in 7%–15% of healthy adults and up to 50% of residents of long-term care facilities [3]. Our patient might have contracted *C. difficile* during his first hospital admission, or a community-acquired colonization might have occurred. Asymptomatic *C. difficile* carriers show skin and environmental contamination [29]. Spores of asymptomatic carriers can easily be transmitted as skin and hand disinfectants do not inactivate spores. The presented patient had asymptomatic intestinal colonization. Skin contamination of multiple body sites could have occurred, resulting in a risk of periprocedural pacemaker contamination. Swabs taken before reimplantation remained negative; nevertheless skin contamination preceding the initial implantation cannot be ruled out, as no testing was initially performed.

For pacemaker implantations, infection prevention measures such as special procedure room, double gloving, annual hygiene inspections, and glucoprotamin-based surface disinfection (Incidin Plus 0.5%, exposure time 30 minutes) are in place at our institution. Povidone-iodine solution (exposure time 1 minute) was used for preoperative skin antisepsis during all procedures; however, this preparation has no sporicidal efficacy in short-term application. At this point, the route of infection in our patient remains unclear, but contamination during the implantation procedure seems to be the more likely route of infection. We present a highly unique case of pacemaker pocket infection, lead endocarditis, and bacteremia with *C. difficile*. This is the first reported case of *C. difficile* causing a cardiac device infection, and it is unique, as no acute gastrointestinal inflammatory pathologies or diarrhea was present. Given the high numbers of asymptomatic *C. difficile* carriers and the growing use of cardiac implantable electronic devices, it remains unclear why this problem has not become apparent before.

Until now, *C. difficile* bacteremia has been associated with underlying gastrointestinal pathologies, severe comorbidities, and immunosuppression. In our patient, none of these was the case. Hence CDI would never have been suspected. With rising numbers of implanted cardiac electronic devices and the high incidence of *C. difficile* infections and colonizations, bloodstream and device infections with *C. difficile* might be a potentially growing issue. Recommendations for management of extra-intestinal *C. difficile* infection risk and treatment are needed.

References

1. Kuipers EJ, Surawicz CM. *Clostridium difficile* infection. Lancet **2008**; 371:1486–8.
2. Goudarzi M, Seyedjavadi SS, Goudarzi H, et al. *Clostridium difficile* infection: epidemiology, pathogenesis, risk factors, and therapeutic options. Scientifica (Cairo) **2014**; 2014:916826.
3. Furuya-Kanamori L, Marquess J, Yakob L, et al. Asymptomatic *Clostridium difficile* colonization: epidemiology and clinical implications. BMC Infect Dis **2015**; 15:516.
4. Gerding DN, Johnson S, Rupnik M, Aktories K. *Clostridium difficile* binary toxin CDT: mechanism, epidemiology, and potential clinical importance. Gut Microbes **2014**; 5:15–27.
5. Debast SB, Bauer MP, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for *Clostridium difficile* infection. Clin Microbiol Infect **2014**; 20(Suppl 2):1–26.
6. Davies KA, Ashwin H, Longshaw CM, et al. Diversity of *Clostridium difficile* PCR ribotypes in Europe: results from the European, multicentre, prospective, biannual, point-prevalence study of *Clostridium difficile* infection in hospitalised patients with diarrhoea (EUCLID), 2012 and 2013. Euro Surveill **2016**; 21:10.2807/1560-7917.ES.2016.21.29.30294.
7. Mattila E, Arkkila P, Mattila PS, et al. Extraintestinal *Clostridium difficile* infections. Clin Infect Dis **2013**; 57:e148–53.

8. Doufair M, Eckert C, Drieux L, et al. *Clostridium difficile* bacteremia: report of two cases in French hospitals and comprehensive review of the literature. IDCases **2017**; 8:54–62.

9. Blomström-Lundqvist C, Traykov V, Erba PA, et al; ESC Scientific Document Group. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections—endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Europace **2020**; 22:515–49.

10. Hussein AA, Baghdy Y, Wazni OM, et al. Microbiology of cardiac implantable electronic device infections. JACC Clin Electrophysiol **2016**; 2:498–505.

11. Narducci ML, Di Monaco A, Pelargonio G, et al. Presence of 'ghosts' and mortality after transvenous lead extraction. Europace **2017**; 19:432–40.

12. Harrison JL, Prendergast BD, Sandoe JA. Guidelines for the diagnosis, management and prevention of implantable cardiac electronic device infection. Heart **2015**; 101:250–2.

13. Berger FK, Rasheed SS, Araj GF, et al. Molecular characterization, toxin detection and resistance testing of human clinical *Clostridium difficile* isolates from Lebanon. Int J Med Microbiol **2018**; 308:358–63.

14. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for *Clostridium difficile* infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis **2018**; 66:e1–48.

15. Hagiya H, Kimura K, Ueda A, et al. Infective thoracic aortic aneurysm caused by *Clostridium difficile* after endovascular aortic repair. J Infect Chemother **2017**; 23:62–4.

16. Shah K, Brauch R, Cherabuddi K. Successful treatment of *Clostridium difficile* bacteremia with aortic mycotic aneurysm in a patient with prior endovascular aortic aneurysm repair. Case Rep Infect Dis **2017**; 2017:8472930.

17. Tsukioka K, Takahashi K, Gomibuchi T, et al. Mycotic iliac artery aneurysm caused by *Clostridium difficile* in a patient with axillobifemoral bypass for leriche syndrome. Ann Vasc Dis **2013**; 6:87–90.

18. Samsky MD, DeVore AD, Durkin M, et al. Getting to a man's heart through his colon. Tex Heart Inst J **2016**; 43:168–70.

19. Sathyendran V, Riley TV, Roberts SA, Freeman JT. Mycotic abdominal aortic aneurysm caused by toxigenic *Clostridium difficile*. Anaerobe **2012**; 18:270–2.

20. Dauby N, Libois A, Van Broeck J, et al. Fatal community-acquired ribotype 002 *Clostridium difficile* bacteremia. Anaerobe **2017**; 44:1–2.

21. Kazanji N, Gjeorgjievski M, Yadav S, et al. Monomicrobial vs polymicrobial *Clostridium difficile* bacteremia: a case report and review of the literature. Am J Med **2015**; 128:e19–26.

22. Feuerstadt P, Das R, Brandt LJ. Diverticular disease of the colon does not increase risk of repeat *C. difficile* infection. J Clin Gastroenterol **2013**; 47:426–31.

23. Dayananda P, Wilcox MH. A review of mixed strain *Clostridium difficile* colonization and infection. Front Microbiol **2019**; 10:692.

24. Kamboj M, Khosa P, Kaltsas A, et al. Relapse versus reinfection: surveillance of *Clostridium difficile* infection. Clin Infect Dis **2011**; 53:1003–6.

25. Baddour LM, Epstein AE, Erickson CC, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; Council on Cardiovascular Disease in Young; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Nursing; Council on Clinical Cardiology; Interdisciplinary Council on Quality of Care; American Heart Association. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation **2010**; 121:458–77.

26. Aljabri K, Garlitski A, Weinstock J, Madias C. Management of device infections. Card Electrophysiol Clin **2018**; 10:153–62.

27. Uslan DZ, Sohail MR, Friedman PA, et al. Frequency of permanent pacemaker or implantable cardioverter-defibrillator infection in patients with gram-negative bacteremia. Clin Infect Dis **2006**; 43:731–6.

28. Bobulsky GS, Al-Nassir WN, Riggs MM, et al. *Clostridium difficile* skin contamination in patients with *C. difficile*-associated disease. Clin Infect Dis **2008**; 46:447–50.

29. Crobach MJT, Vernon JJ, Loo VG, et al. Understanding *Clostridium difficile* colonization. Clin Microbiol Rev **2018**; 31:e00021-17.